Krystal Biotech (KRYS) Superinvestor holders
12 of the superinvestors we track hold Krystal Biotech (KRYS) in their latest 13F filings, $76M in total.
Summary
The largest holder is Jim Simons (Renaissance Technologies), with $22M, 0.0% of the portfolio.
In their latest quarter: 3 opened a new position, 4 added, 4 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Jim Simons Renaissance Technologies |
Added | 59,680 | $22M | 0.0% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
Added | 54,489 | $20M | 0.1% | Q2 2026 |
| Ken Fisher Fisher Investments |
Trimmed | 26,952 | $9M | 0.0% | Q3 2026 |
| WCM Investment Management | New position | 15,753 | $6M | 0.0% | Q2 2026 |
| Eddie Brown Brown Capital Management |
Added | 16,079 | $5M | 1.0% | Q3 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 14,002 | $5M | 0.0% | Q2 2026 |
| Robert Torray Torray Investment Partners |
Trimmed | 8,370 | $3M | 0.4% | Q3 2026 |
| Two Sigma Two Sigma Investments |
New position | 6,084 | $2M | 0.0% | Q2 2026 |
| Alger Fred Alger Management |
New position | 5,418 | $2M | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Held | 1,369 | $508,816 | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Added | 1,330 | $494,321 | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Trimmed | 216 | $71,000 | 0.0% | Q3 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 12 |
| Q1 2026 | 12 |
| Q4 2025 | 12 |
| Q3 2025 | 9 |
| Q2 2025 | 9 |
| Q1 2025 | 11 |
| Q4 2024 | 9 |
| Q3 2024 | 10 |
Questions about Krystal Biotech
Which superinvestors own Krystal Biotech?
12 of the superinvestors we track hold Krystal Biotech (KRYS) in their latest 13F filings, $76M in total. Jim Simons, Ray Dalio, Ken Fisher, WCM Investment Management, Eddie Brown, Cliff Asness.
Who is the largest superinvestor holder of KRYS?
The largest holder is Jim Simons (Renaissance Technologies), with $22M, 0.0% of the portfolio.
From Krystal Biotech's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.